Chemotherapy delay after primary debulking surgery for ovarian cancer

摘要: Abstract Objective To determine the association of chemotherapy delay with overall survival (OS) and investigate predictors among a population-representative American ovarian cancer cohort. Methods An observational retrospective cohort analysis women who received National Comprehensive Cancer Network guideline-consistent care was performed 1998–2011 Data Base. Chemotherapy defined as initiation multiagent >28days from primary debulking surgery. Associations patient disease characteristics were tested multivariate logistic regression. Survival analyses for diagnosed 2003 to 2006 approximated 21-daycycle intravenous platinum-taxane Overall estimated by Kaplan-Meier Cox proportional-hazards regressions, sensitivity using matched cohorts. Results 58.1% (26,149/45,001) experienced delay. Race, insurance status, center type, community median income significantly associated ( P 35days surgery 7% (95% confidence interval, 2–13%) increased hazard death =0.01). Relative lowest between 25 29days after but not different within longer two-week interval 21 35days. Conclusion A benefit may be achieved consistently starting Women at higher risk targeted close follow-up.